Treatment outcome in patients with HCV Genotype-3a Infection, Treated with 24-Weeks Dual Therapy (Sofosbuvir and Ribavirin). mfm. 2024;28(11). Accessed May 22, 2026. https://medicalforummonthly.com/index.php/mfm/article/view/4275